Buscar
Verrica Pharmaceuticals Inc
VRCAAñadir a la lista de seguimiento
6.135USD
+0.195+3.28%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
105.39MCap. mercado
PérdidaP/E TTM
Más Datos de Verrica Pharmaceuticals Inc Compañía
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Información de Verrica Pharmaceuticals Inc
Símbolo de cotizaciónVRCA
Nombre de la empresaVerrica Pharmaceuticals Inc
Fecha de salida a bolsaJun 15, 2018
Director ejecutivoRieger (Jayson)
Número de empleados71
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 15
Dirección44 West Gay Street
CiudadWEST CHESTER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal19380
Teléfono14844533300
Sitio Webhttps://verrica.com/
Símbolo de cotizaciónVRCA
Fecha de salida a bolsaJun 15, 2018
Director ejecutivoRieger (Jayson)
Ejecutivos de Verrica Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
183.29K
-0.00%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
21.00K
+47.62%
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
2.36K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Chairman of the Board
Chairman of the Board
--
--
Mr. Mark A. Prygocki, Sr.
Mr. Mark A. Prygocki, Sr.
Independent Director
Independent Director
--
--
Dr. Lawrence Eichenfield, M.D.
Dr. Lawrence Eichenfield, M.D.
Independent Director
Independent Director
--
--
Mr. John J. Kirby
Mr. John J. Kirby
Interim Chief Financial Officer, Interim Principal Financial Officer
Interim Chief Financial Officer, Interim Principal Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
183.29K
-0.00%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
21.00K
+47.62%
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
2.36K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Chairman of the Board
Chairman of the Board
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Verrica Pharmaceuticals Inc?
Los cinco principales accionistas de Verrica Pharmaceuticals Inc son: Dr. Jayson Rieger
¿Cuántas instituciones poseen acciones de Verrica Pharmaceuticals Inc (VRCA)?
A fecha de 2026Q1, 180 instituciones poseen acciones de Verrica Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 5.43M, lo que representa el 31.63% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 1273710.00.